Insights / Function
Posts carrying the Go-to-Market tag.
29 Aug 2024 · 1 min read
Big Pharma is increasingly jumping on the direct-to-consumer bandwagon in the U.S., with Lilly Direct, Pfizer-For-All, and others following the trail blazed by Ro and Hims/Hers. I'm asking whether this could be the moment when Pharma's business model truly evolves — and whether these companies can finally engage directly with patients.
26 Aug 2024 · 1 min read
Following Pear's bankruptcy, their FDA-cleared DTx apps reSET and reSET-O have been relaunched by PursueCare — and I think it's a timely reminder that we may have been overly optimistic about digital therapeutics succeeding independently, and that go-to-market strategy deserves an open mind.
1 May 2024 · 2 min read
I just got back from two packed days at LSX2024 in London, where I joined panels on pharma's path to launching digital health products and shared how QuantHealth will transform clinical trial design. Here are my key takeaways from the healthtech track.